These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20482436)

  • 1. Practical limitations of prescribing olanzapine depot (Relprevv).
    Devadason P
    Australas Psychiatry; 2010 Jun; 18(3):269. PubMed ID: 20482436
    [No Abstract]   [Full Text] [Related]  

  • 2. [Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice].
    Sümegi A; Kálmán J; Csekey L
    Neuropsychopharmacol Hung; 2013 Jun; 15(2):105-17. PubMed ID: 23817361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis.
    Solfanelli A; Curto M; Dimitri-Valente G; Kotzalidis GD; Gasperoni C; Sani G; Manfredi G; Rapinesi C; Comparelli A; Girardi P
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):232-4. PubMed ID: 23607414
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder.
    Legrand G; Andrianarisoa M; Mauvieux J; Jalenques I
    J Clin Psychopharmacol; 2014 Oct; 34(5):652-3. PubMed ID: 25006816
    [No Abstract]   [Full Text] [Related]  

  • 5. [Depot antipsychotics in the year 2011].
    Knegtering H; Oolders H; Ruijsink MA; van der Moolen AE
    Tijdschr Psychiatr; 2011; 53(2):95-105. PubMed ID: 21319066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial.
    Thompson A; Sullivan SA; Barley M; Strange SO; Moore L; Rogers P; Sipos A; Harrison G
    Psychol Med; 2008 May; 38(5):705-15. PubMed ID: 17825122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving patients' drug compliance.
    DeProspero T; Riffle WA
    Psychiatr Serv; 1997 Nov; 48(11):1468. PubMed ID: 9355180
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term treatment with neuroleptics in psychiatry.
    Shepherd M; Watt DC
    Curr Dev Psychopharmacol; 1977; 4():215-47. PubMed ID: 23248
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-acting injectable olanzapine can give rise to a condition consistent with central anticholinergic syndrome.
    Skomedal T; Hanem S; Dybvik T; Ilner SO
    Tidsskr Nor Laegeforen; 2013 Nov; 133(21):2238-9. PubMed ID: 24226327
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting.
    Simpson JR; Thompson CR; Beckson M
    J Clin Psychopharmacol; 2006 Jun; 26(3):333-5. PubMed ID: 16702903
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors affecting compliance with depot injection treatment in the community.
    Tunnicliffe S; Harrison G; Standen PJ
    Soc Psychiatry Psychiatr Epidemiol; 1992 Oct; 27(5):230-3. PubMed ID: 1359653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset neuroleptic malignant syndrome in a patient using olanzapine.
    Kunz M; Gomes FA; Tramontina JF; Kapczinski F
    J Clin Psychopharmacol; 2007 Jun; 27(3):303-4. PubMed ID: 17502780
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversible delayed onset olanzapine-associated leukopenia and neutropenia in a clozapine-naive patient on concomitant depot antipsychotic.
    Thinn SS; Liew E; May AL; Chua HC; Sim K
    J Clin Psychopharmacol; 2007 Aug; 27(4):394-5. PubMed ID: 17632225
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of akathisia after switching from branded to generic high-dose olanzapine.
    Goldberg JF
    J Clin Psychiatry; 2012 Apr; 73(4):497. PubMed ID: 22579148
    [No Abstract]   [Full Text] [Related]  

  • 16. Olanzapine and delirium: lesson from clinical practice.
    Singh D; Forlano R
    Aust N Z J Psychiatry; 2008 May; 42(5):433-4. PubMed ID: 18499932
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: a case report.
    Marks DM; Conner MJ; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):386-7. PubMed ID: 19166898
    [No Abstract]   [Full Text] [Related]  

  • 18. [Post-injection syndrome after depot injection of olanzapine].
    Wilms EB; van der Velden MT; van Essen FH; ten Brink C
    Ned Tijdschr Geneeskd; 2014; 159():A7885. PubMed ID: 25589277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
    Gastpar M; Masiak M; Latif MA; Frazzingaro S; Medori R; Lombertie ER
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):32-8. PubMed ID: 16144784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between smoking and psychotic symptoms in a patient treated with oral olanzapine. A case report.
    Leal-Micharet A; Vaz-Leal FJ; Méndez-Salguero MJ; Méndez-Sánchez F; Baltasar-Tello I; Gómez-Tovar B; Gajardo-Galán V
    Actas Esp Psiquiatr; 2014; 42(5):263-6. PubMed ID: 25179099
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.